<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00939367</url>
  </required_header>
  <id_info>
    <org_study_id>US/05/004</org_study_id>
    <nct_id>NCT00939367</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Zolpidem Tartrate Tablets Under Fed Conditions</brief_title>
  <official_title>Randomized, Two Period Crossover Studies in Fed Healthy, Normal Subjects to Compare the Single Dose Bioavailability of Torrent's Zolpidem Tartrate Tablets 10 mg and Sanofi-Synthelabo's Ambien® 10 mg Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects to compare the single dose bioavailability of Torrent's Zolpidem Tartrate Tablets
      10mg and Ambien® Tablets 10 mg of Sanofi-Synthelabo Inc.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open Label, Randomized, 2-period, 2- Treatment, 2-Sequence, Crossover, Single-dose
      Bioequivalence Study of Zolpidem Tartrate Tablets containing Zolpidem Tartrate 10 mg ( Test
      Formulation, Torrent Pharmaceutical Ltd., India) Versus Ambien® Tablets 10 mg containing
      Zolpidem Tartrate 10 mg (Reference , Sanofi-Synthelabo Inc) in Healthy Human Volunteers Under
      Fed Condition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2007</start_date>
  <completion_date type="Actual">May 2, 2007</completion_date>
  <primary_completion_date type="Actual">May 2, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.</time_frame>
    <description>The maximum or peak concentration that the drug reaches in the plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]</measure>
    <time_frame>plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.</time_frame>
    <description>The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)</measure>
    <time_frame>plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.</time_frame>
    <description>The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Torrent's Zolpidem TartrateTablets 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sanofi-Synthelabo Inc's Ambient® Tablets 10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem Tartrate Tablets 10 mg</intervention_name>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>'Sanofi-Synthelabo Inc's Ambien® Tablets 10 mg</intervention_name>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subjects who qualify for the study should meet the following inclusion criteria.

               1. Male and female subjects in the range of 18 - 45 years of age.

               2. Subjects having Body Mass Index (BMI) in a range of 18.5 to 24.9.

               3. Subjects with normal findings as determined by baseline history, physical
                  examination and vital signs (blood pressure, pulse rate, respiration rate and
                  body temperature)

               4. Subjects with normal findings as determined by hematological tests, serum
                  chemistry, urine analysis, ECG and X-ray.

               5. Willingness to follow the protocol requirement as evidenced by written, informed
                  consent.

               6. Agreeing to, not using any medication prescription and over the counter medicines
                  including vitamins and minerals for 14 days prior to study and during the course
                  of the study.

               7. No history or presence of significant alcoholism or drug abuse in the past one
                  year.

               8. Non-smokers, ex smokers and light smokers will be included. &quot; Light smokers are
                  defined as someone smoking 10 cigarettes or less per day, ex smokers as someone
                  who completely stopped smoking for at least 3 months.

        Exclusion Criteria:

          -  The subjects who qualify for the study should not meet the following exclusion
             criteria:

               1. Requiring medication for any ailment including enzyme-modifying drugs in the
                  previous 28 days, before day1.

               2. Any medical or surgical conditions, which might significantly interfere with the
                  functioning of gastrointestinal tract, blood-forming organs etc.

               3. History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological,
                  metabolic diseases.

               4. Participation in a clinical drug study or bioequivalence study 90 days prior to
                  present study.

               5. History of malignancy or other serious diseases.

               6. Refusal to abstain from food for at least ten (10) hours prior to High Fat
                  Breakfast and for additional four (4) hours post dose during each study period.

               7. Refusal to abstain from water for at least one (1) hour prior to study drug
                  administration on each study period and for at least two (2) additional hours,
                  post dosing.

               8. Any contraindication to blood sampling.

               9. Use of xanthine-containing beverages or food and grapefruit juice for 48 hours
                  prior to each drug dose.

              10. Blood donation 90 days prior to the commencement of the study.

              11. Subjects with positive HIV tests, HbsAg or Hepatitis-C tests.

              12. Known history of hypersensitivity to zolpidem Tartrate or to any of the inactive
                  ingredients in the formulation.

              13. Refusal to abstain from smoking or consumption of tobacco products 24 hours
                  before dosing until last sample collection of each period.

              14. Pregnant and lactating women.

              15. Use of prescription medication within 14 days prior to administration of study
                  medication or over the counter products (including natural food
                  supplements,vitamins, garlic as a supplement) within 14 days prior to
                  administration of study medication, except for topical products without systemic
                  absorption.

              16. Female subjects whose menstruation cycle coincides with the study periods.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Accutest Research Laboratories Pvt. Ltd.</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>July 13, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2009</study_first_posted>
  <results_first_submitted>July 22, 2009</results_first_submitted>
  <results_first_submitted_qc>October 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 14, 2013</results_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>healthy, normal subjects</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Torrent's Zolpidem First, Then Ambien</title>
          <description>For period one - on the morning of Day 1 subjects received Torrent's Zolpidem 10 mg.
Followed by a 7 day washout period.
For period two - on the morning of Day 1 subjects received the reference formulation, Ambien 10 mg.</description>
        </group>
        <group group_id="P2">
          <title>Ambien First, Then Torrent's Zolpidem</title>
          <description>For period one - on the morning of Day 1 subjects received the reference formulation, Ambien 10 mg
Followed by a 7 day washout period.
For period two - on the morning of Day 1 subjects received the test formulation, Torrent's Zolpidem 10 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Torrent's Zolpidem Tartrate Tablets 10 mg and Ambien® 10mg tablets</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="7.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax)</title>
        <description>The maximum or peak concentration that the drug reaches in the plasma</description>
        <time_frame>plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Torrent's Zolpidem Tartrate Tablets 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator</title>
            <description>Ambien® 10mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax)</title>
          <description>The maximum or peak concentration that the drug reaches in the plasma</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.58" spread="40.61"/>
                    <measurement group_id="O2" value="124.53" spread="37.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]</title>
        <description>The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t)</description>
        <time_frame>plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Torrent's Zolpidem Tartrate Tablets 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator</title>
            <description>Ambien® 10mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]</title>
          <description>The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t)</description>
          <units>ng.hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="734.29" spread="416.53"/>
                    <measurement group_id="O2" value="705.45" spread="356.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)</title>
        <description>The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
        <time_frame>plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Torrent's Zolpidem Tartrate Tablets 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator</title>
            <description>Ambien® 10mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)</title>
          <description>The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
          <units>ng.hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="776.65" spread="484.20"/>
                    <measurement group_id="O2" value="734.01" spread="384.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Experimental</title>
          <description>Torrent's Zolpidem Tartrate Tablets 10 mg</description>
        </group>
        <group group_id="E2">
          <title>Active Comparator</title>
          <description>Ambien® 10mg tablets</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Regurgitation of water and food content</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Giddiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kedar Joshi</name_or_title>
      <organization>Accutest Research Laboratories Pvt. Ltd.</organization>
      <phone>+91 22 27780718</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

